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CUTANEOUS MICROVASCULATURE OF HUMAN CHRONIC GVHD LACKS
THE VASCULAR RAREFACTION OR THE ABNORMAL ENDOTHELIAL
CELL PHENOTYPE OF SYSTEMIC SCLEROSIS
Fleming, J.N.1, Shulman, H.M.2, Schwartz, S.M.1 1University of Wash-
ington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, Seattle,
WA
Background: Though endstage human cutaneous c-GVHD and
systemic sclerosis (SSc) appear histologically similar, structural
changes of small vessels in the superficial dermal microvasculature
(SDM)and dermis of affected skin have not been comprehensively
compared. We addressed the question: does c-GVHD have micro-
vascular alterations similar to those in SSc making it a suitable path-
ogenetic model for SSc?
Methods: We analyzed skin biopsies from 30 SSc and 13 c-
GVHD both with a range of dermal fibrosis scores (DFS) Blood
2007:110,1388, and 24 normal controls. DFS was based on H&E
stained collagen and dermal matrix changes in full thickness skin bi-
opsies. Immunostaining of SDM with physiologic endothelial (ED)
Ab’s to vWF,CD31, and VECadherin (VEC) were used for defining
ED phenotype and vessel quantification. Ab’s for smooth muscle ac-
tin, smooth muscle myosin heavy chain and hyaluronan were also
used to identify formation of intima and highlight vascular wall
smooth muscle changes.
Results: In c-GVHD the dermal fibrosis typically progressed in
a top down progression whereas in SSc it was a bottom up pattern.
The pansclerotic endstage of both conditions had similar dermalma-
trix composition and smooth muscle pathology (including intimal
hyperplasia) significantly different from normals. C-GVHD signifi-
cantly differed fromSSC in several ways: 1. Average vessel count in c-
GVHD 16.5 vs 9.8 Scc (p5\0.0001), 2. In addition, c-GVHD had
no loss of the important canonical EDmarkers VEC and vWF, both
0/13 whereas both VEC and vWF were decreased compared with
CD31 expression (19/19 and 12/14 respectively) in SSc (p 5 \
0.0001 and\0.05), respectively). 3. Lastly, c-GVHD had areas of
microvascular ED proliferation absent in the SSc biopsies.
Conclusion: C-GVHD shares some histologic features with SSc
but the progression of the dermal fibrosis appears different. The
ED markers in c-GVHD remain constant, whereas in contrast, in
SSc an intrinsically abnormal anti-angiogenic ED cell phenotype
with loss of the canonical ED markers vWF and VEC may be re-
lated to the microvascular rarefaction and lack of angiogenesis.
PloS One 2008:3: e1452 VEC in particular is required for the for-
mation of endothelial tubes in vitro and in vivo, and loss of its ex-
pression in SSc may contribute to the loss of capillaries in SSc skin.
C-GVHD is a suitable model for studying dermal sclerosis, but
probably not suitable for studying the microvascular changes in
Scc.88
INCIDENCE OF CMV INFECTION IN AUTOIMMUNE DISEASES AFTER AU-
TOLOGOUS STEM CELL TRANSPLANTATION
Pieroni, F.1, Stracieri, A.B.P.1, Oliveira, M.C.B.1, Morais, D.A.1,
Barros, G.M.1, Madeira, M.I.A.1, Simoes, B.P.2, Voltarelli, J.C.2 1Clin-
ical Hospital of the School of Medicine of Ribeira˜o Preto of the University of
Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paulo, Brazil; 2School of Medicine of
Ribeira˜o Preto of the University of Sa˜o Paulo, Ribeira˜o Preto, Sa˜o Paulo,
Brazil
Autoimmune diseases have been successfully treated with high-
dose immunosuppression followed by ASCT. There is no report re-
garding the incidence of CMV infection in this subset of patients.
We report here the incidence of CMV infection in 88 consecutive
ASCT for autoimune disease. Table 1 shows patients characteristics.
Before ASCT, all patients were seropositive for CMV. The used36conditioning regimens were BEAM 1 hATG 30mg/Kg for 11 MS
patients, and Cy 200mg/Kg 1 rATG 4,5mg/Kg for the other pa-
tients. All patients received peripheral blood as the source of stem
cells. Blood red cells and platelets infused were all irradiated and fil-
trated. The blood CMV pp65 antigen test was based on the mono-
clonal antibody against the virus and immunofluorescence. CMV
infection was defined as a positivity of at least one pp65 antigenemia
assay at any level. A CMVpp65 antigenemia assay was determined
weekly, starting from the day when the absolute neutrophil count
went above 500  103/ul, and until day 60 after ASCT. Patients
with five or more positive CMV cells, in use of corticosteroids
with any number of positive CMV cells and with any clinical signs
of CMV disease with any number of positive CMV cells were treated
with Gancyclovir. Among the 88 transplanted patients, 20,5% pre-
sented a positive antigenemia. The first positive antigenemia pre-
sented a median of 19 days after stem cell reinfusion (range 05 to
52). The median antigenemia level at the first appearance was 2 in-
fected cells (range 1–40). Overall, 07 patients were treated with Gan-
cyclovir. Five were treated preemptively. Two patients had CMV
pneumonits, and one died from it. In 61% of the cases, CMV reac-
tivation was asymptomatic with less them 5 cells positive and antige-
nemia has cleared spontaneously. Our study shows that CMV
infection can reactivate in a significant proportion of seropositive pa-
tients after ASCT. However, despite the use of Antimocyte Globu-
lin, the rate of CMV reactivation in this subset of patients seens
not be different from the rate of reactivation recently encountered af-
ter ASCT for hematologic malignancies (Rossini, F., et al, Transpl
Infect Dis 2005: 7: 122–125). Moreover, in spite of the fact that
CMV infection was asymptomatic and antigenemia clears spontane-
ously in a proportion of the cases, if we consider the severity of CMV
disease, its high rate of mortality, and the high costs of treating it, we
think that these results can justify surveillance in seropositive pa-
tients.
Table 1Patients characteristicsTransplanted patients 88
Median age 34 (13-55)
Female/Male ratio 3:1
Autoimmune disease Number of patients
Multiple Sclerosis 45
Type 1 Diabetes Mellitus 22
Systemic Sclerosis 09
Systemic Lupus Eritematous 04
Neuromyelitis Optica 04
Amyotrophic Lateral Sclerosis 02
Vulgar Pemphigus 01
Takayasu Arteritis 01AUTOLOGOUS TRANSPLANTS
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COMPARISON OF CLINICAL OUTCOMES OF RELAPSED APL PATIENTS
INDUCED WITH ATO AND CONSOLIDATED WITH EITHER AN AUTOLO-
GOUS SCT OR ATO BASED TREATMENT REGIMEN
Mathews, V., George, B., Lakshmi, K.M., Chendamarai, E.,
Viswabandya, A., Srivastava, A., Chandy, M. Christian Medical College,
Vellore, Tamil Nadu, India
Arsenic trioxide (ATO) is the most effective agent in inducing
remission among patients with relapsed acute promyelocytic
leukemia (APL). After induction of remission in relapsed patients
with ATO the best consolidation regimen remains to be defined.
Since January 2000, 37 patients with relapsed APL were treated
at our center. The median age was 34 years (range: 6 – 57) and
there were 20 (54.1%) males. The initial treatment was conven-
tional ATRA plus chemotherapy in 23 (62.2%) and single agent
ATO in 14 (37.8%). The median duration of first remission was
Poster Session-I 3720.3 months (range: 2.9 – 81.2). Relapse was treated with single
agent ATO in 22 (59.5%), with ATO1ATRA in 5(13.5%) and
with ATO1ATRA1anthracycline in 10 (27%). Thirty five
(94.5%) achieved CR (two early deaths). After remission induction,
a consolidation course of the same agents used in induction was ad-
ministered (ATO and ATRA were administered for 28 days), 34
(92%) achieved molecular remission after this course. All patients
who achieved molecular remission were offered an autologous
SCT. Fourteen patients opted to have an autologous SCT and
the remaining patients were scheduled to receive monthly cycles
of ATO as a single agent (n 5 14) or ATO1ATRA (n 5 7) for
6 months. The age, sex, duration of first CR, induction and consol-
idation regimen used to treat relapse was comparable between the
patients that underwent an autologous SCT and the remaining pa-
tients. Patients who underwent an autologous SCT were condi-
tioned with a conventional Bu/Cy regimen and received PBSC
graft with a median cell dose of 5.3  106 CD34/Kg (range: 3.54
– 9.24). There were no treatment related deaths following the au-
tologous SCT, one patient had an isolated CNS relapse 6 months
post transplant. There were no other relapses or deaths in this
group. Among the remaining patients who achieved CR but did
not have an autologous SCT (n 5 21), 16 relapsed and all except
one of these patients eventually died of progressive disease at me-
dian period of 1.6 months from second relapse (range: 0 – 42.6).
At a median follow up of 24 months, the 3-year Kaplan-Meier es-
timate of EFS among those who received an autologous SCT vs.
those that did not was 92.866.8 vs. 28.769.7 (log rank: P 5
0.003). Following remission induction with ATO based regimens
in patients with relapsed APL, consolidation with an autologous
SCT is associated with a significantly superior clinical outcome
in comparison to alternative ATO / ATRA based maintenance
regimens.90
EFFECT OF PLERIXAFOR (AMD 3100) PLUS G-CSF ON TUMOR CELL
MOBILIZATION AMONG PATIENTS WITH LYMPHOMA
DiPersio, J.F.1, Bridger, G.2, Calandra, G.2 1Washington University, St.
Louis, MO; 2Genzyme Corporation, Cambridge, MA
Introduction: Plerixafor used with G-CSF has been shown to
rapidly and predictably increase peripheral blood CD341
cells. This report evaluates the effect of G-CSF with or without
plerixafor on tumor cell mobilization in patients with lym-
phoma.
Methods: This is a retrospective evaluation of apheresis sam-
ples from patients with a diagnosis of BCL-2 positive non-Hodg-
kins lymphoma that were enrolled in either a pivotal Phase III
(3101) or Phase II (2101) study assessing the safety and efficacy
of plerixafor in hematopoietic stem cell mobilization. To assess
tumor cell mobilization, samples from apheresis products were
assayed by real-time quantitative polymerase chain reaction
(PCR) to quantify major breakpoint region (MBR) translocation
of the BCL-2 gene and normalized to B-actin. Standard curves
for the BCL-2 rearrangement and B-actin were generated to
quantify DNA levels within each sample. A result of undetectable
levels of the t(14;18) translocated BCL-2 gene indicated an ab-
sence of mobilized tumor cells.
Results: Apheresis samples from 11 BCL-2 positive lymphoma
patients, 8/ 298 patients enrolled in 3101 and 3/25 patients enrolled
in 2101, were evaluated for evidence of tumor cell mobilization. The
age of patients ranged from 47 to 66 years and majority of the pa-
tients were women (8/11 patients). Six patients were diagnosed
with follicular lymphoma while the remainder had diffuse large
cell lymphoma. Five patients received G-CSF alone and 6 patients
received a combination of G-CSF and plerixafor. Between 0.70 
106 CD341 cells/kg and 10.12  106 CD341 cells/kg were mobi-
lized within four apheresis days. Quantification by real-time PCR
demonstrated that 10 of the 11 patients had undetectable levels of
translocated BCL-2 in the leukapheresis product. One patient who
was treated with G-CSF alone had detectable levels of the BCL-2
translocation.
Conclusions: These findings are consistent with other phase II
clinical studies, which reported negligible tumor cell mobilization
after plerixafor treatment.91
PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM
CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED
WITH LENALIDOMIDE
Tarantolo, S.R.1, McSweeney, P.A.2, Micallef, I.N.M.3, Klein, L.M.4,
Calandra, G.5, Huebner, D.5 1Nebraska Methodist Hospital, Omaha,
NE; 2Rocky Mountain Cancer Center, Denver, CO; 3Mayo Clinic, Ro-
chester, MN; 4Advocate Lutheran General Hospital, Niles, IL; 5Genzyme
Corporation, Cambridge, MA
Introduction: Emerging literature suggests that lenalidomide
negatively affects the ability to collect CD341 cells in patients
with multiple myeloma (MM) undergoing hematopoietic stem cell
transplantation. The aim of this retrospective subgroup analysis is
to examine the efficacy of mobilization with plerixafor 1 G-CSF
(P1G) among patients previously treated with lenalidomide.
Methods: Patients withMMwho participated in a phase III study
(3102) assessing the safety and efficacy of plerixafor in hematopoietic
stem cell mobilization or in a compassionate use program (CUP)
who received P1G and that had complete data on number of cycles
of lenalidomide and total CD34 1 cells collected were analyzed.
Trial designs of the aforementioned studies have been described pre-
viously (DiPersio ASH 2007, Calandra BMT 2007). Briefly, in study
3102, patients received P1G as a first line mobilization regimen,
whereas patients in the CUP received P1G as rescue therapy after
failing other mobilization regimens.
Results: Of the 148 patients randomized to P1G in 3102,
seven patients were previously treated with lenalidomide. In the
CUP database, 60/708 patients were previously treated with lena-
lidomide. Complete data on number of cycles of lenalidomide
and total CD341 cells collected was available for 27 patients;
five from 3102 and 22 from CUP. The mean age was
61.267.9 years and 14/27 (52%) of the patients were men.
The median number of lenalidomide cycles prior to mobilization
was four (range 1–20). Administration of P1G resulted in a me-
dian collection of 4.3  106 CD341 cells/kg. A total of 20/27
(74%) of the patients collected $ 2  106 CD341 cells/kg in
a median of two apheresis sessions. All the patients in 3102 col-
lected $ 2  106 CD341 cells/kg compared to 15/22 (68%) of
the patients in CUP. Overall, 22 (81.5%) patients proceeded to
transplant. Median time to neutrophil and platelet engraftment
was 11.5 days and 18 days, respectively.
Pooled DataStudy 3102








14.8 (4.6–22.2) 3.29 (0.45–13.53) 4.3 (0.45–22.2)Percent of Patients
that Collected $
5  106 CD341
cells/kg4/5 (80%) 7/22 (32%) 11/27 (41%)Percent of Patients that
Collected $ 2  106
CD341 cells/kg5/5 (100%) 15/22 (68%) 20/27 (74%)Median Time (in days)
to Neutrophil
Engraftment (Range)12 (11–13) 11 (10–16) 11.5 (10–16)Median Time (in days)
to Platelet
Engraftment
(Range)18 (13–22) 18.5 (11–42) 18 (11–42)Conclusions: These preliminary results suggest that the majority
of patients with MM pretreated with lenalidomide can be success-
fully mobilized ($ 2  106 CD341 cells/kg) with P1G.
